An Phase II Clinical Study on the Safety, Tolerability and Efficacy of HRS-7058 in Combination With Antitumor Drugs in Subjects With Solid Tumors
Latest Information Update: 11 Apr 2025
At a glance
- Drugs HRS 7058 (Primary) ; Adebrelimab; Antineoplastics; Cetuximab; SHR 1826
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shandong Suncadia Medicine
- 11 Apr 2025 New trial record